Roberto P. Cid
Zaragoza, AR, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.
Journal: ESMO gastrointestinal oncology
Published: August 12, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.
Journal: ESMO open
Published: August 13, 2025
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.
Journal: Current medical research and opinion
Published: June 18, 2025
Erratum: Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.
Journal: JCO precision oncology
Published: April 03, 2025
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: May 28, 2024
Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report.
Journal: Oncology letters
Published: October 21, 2014
Topological defects and misfit strain in magnetic stripe domains of lateral multilayers with perpendicular magnetic anisotropy.
Journal: Physical review letters
Published: April 26, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026